+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy



Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy



Acta Gastro-Enterologica Belgica 70(1): 20-24



To investigate the efficacy of the combined therapy of lamivudine (LAM) plus alpha interferon (IFN) and LAM monotherapy in HBeAg negative chronic hepatitis B (CHB) patients who were unresponsive to previous IFN monotherapy, and the incidence of YMDD mutations. Forty-five HBeAg negative patients were enrolled in this study. 24 of these were treated with LAM (100 mg/day, PO, for 24 months) alone (group 1) and 21 with combined therapy (IFN-alpha-2b, 10 MU, tiw, SC, for 6 months plus LAM 100 mg/day, PO, for 24 months) (group 2). Normal alanine aminotransferase values and negativity of HBV DNA (molecular hybridization; Digene, USA) were accepted as treatment response. YMDD variants were analyzed at the end of treatment or when clinical breakthrough was observed (Inno-Lipa Innogenetic kit, Belgium). End of follow-up response rate was 29.2%, by ITT in group 1, 19% in group 2 (p > 0.05). Histological activity index was statistically decreased by LAM monotherapy as compared to combination therapy. YMDD mutation rates were 59% in group 1, 62.5% in group 2 (p > 0.05). Additional IFN-alpha therapy to LAM in HBeAg negative CHB not responding to previous IFN-alpha monotherapy does not increase the response rate compared to LAM monotherapy and does not also decrease the incidence of YMDD mutations.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 054066913

Download citation: RISBibTeXText

PMID: 17619534


Related references

Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. Journal of Microbiology, Immunology, and Infection 38(4): 262-266, 2005

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. American Journal of Gastroenterology 100(11): 2463-2471, 2005

Comparison of lamivudine monotherapy with lamivudine plus interferon alpha combination in patients with HBeAg positive chronic hepatitis B. Journal of Hepatology 34(Suppl. 1): 177-178, 2001

Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B. Journal of Gastroenterology and Hepatology 22(10): 1582-1588, 2007

Long term efficacy of interferon and Thymosin combination in comparison to lamivudine+interferon and interferon monotherapy in patients with HBeAg negative chronic hepatitis B. Journal of Hepatology 38(Suppl. 2): 169, 2003

Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clinical Infectious Diseases 36(12): 1516-1522, 2003

Lamivudine monotherapy and interferon plus lamivudine combination therapy in anti-HBe positive patients with chronic hepatitis B who have failed previously interferon treatment. Journal of Hepatology 34(Suppl. 1): 167, 2001

Higher efficacy of sequential therapy of lamivudine and interferon compared to lamivudine monotherapy in HBeAg positive, chronic hepatitis B patients. Gastroenterology 123(1 Suppl.): 69, 2002

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. Journal of Hepatology 35(3): 406-411, 2001

Three-year follow-up of pegylated interferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B. Scandinavian Journal of Gastroenterology 44(8): 1021-1022, 2010

Interferon alpha2a in combination with lamivudine in the treatment of patients with chronic HbeAg hepatitis B non-responders to interferon monotherapy. Journal of Hepatology 36(Suppl. 1): 245, 2002

Higher efficacy of sequential therapy of lamivudine and interferon-A vs lamivudine monotherapy in patients with HBeAg positive chronic hepatitis B A prospective randomized controlled trial. Journal of Hepatology 40(Suppl 1): 131, 2004

Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials. Hepatobiliary and Pancreatic Diseases International 9(5): 462-472, 2011

Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World Journal of Gastroenterology 11(37): 5882-5887, 2005

Comparison of lamivudine and alpha-interferon combination with alpha-interferon alone in the treatment of HBeAg-positive chronic hepatitis B. Indian Journal of Gastroenterology 25(2): 71-73, 2006